BAC
Bank of America Corporation
BAC has lower modeled downside risk, despite its lower overall score.
COHR
Coherent, Inc.
COHR has the edge over BAC overall, supported by stronger modeled upside.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
COHR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Weak | |
| Healthy |
COHR's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC has the edge over COHR in the historical PE scenario, which offers more potential upside but is not a forecast.
COHR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 20x | $232 | — |
| Cheap | 27x | $130 | -44% |
| Fair | 34x | $165 | -29% |
| Current | 48x | $232 | — |
| Expensive | 184x | $886 | +282% |
Historical ranges are pointers, not guarantees.
COHR's PE is in its fair range at 48x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its cheap range.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for BAC, with profitability improving.
COHR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Moderate |
Analysts expect strong earnings and revenue growth for COHR, with profitability improving.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC's earnings per share have climbed steadily: $4.19 over the past year, up 14% from the year before, and higher year over year for eight quarters in a row.
COHR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.69 | +142% |
| Q3 2026 | $4.83 | +580% |
| Q2 2026 | $4.12 | +$4.64 |
| Q1 2026 | $2.11 | +$2.34 |
| Q4 2025 | $1.03 | +$1.44 |
| Q3 2025 | $0.71 | +$1.94 |
| Q2 2025 | -$0.52 | +$1.32 |
| Q1 2025 | -$0.23 | +$2.64 |
| Q4 2024 | -$0.41 | +$2.41 |
COHR's earnings per share have climbed steadily: $4.83 over the past year, about seven times what it earned the year before, and higher year over year for 10 quarters in a row.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC's revenue has grown year over year for 10 quarters in a row: $30B last quarter, up 6.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC has the edge over COHR on profitability, with a higher operating margin.
COHR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.4B | +50% |
| Q2 2026 | $2B | +34% |
| Q1 2026 | $1.8B | +21% |
| Q4 2025 | $1.7B | +17% |
| Q3 2025 | $1.6B | +17% |
| Q2 2025 | $1.5B | +16% |
| Q1 2025 | $1.5B | +24% |
| Q4 2024 | $1.4B | +27% |
COHR has the edge over BAC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | +1.4 points |
| Q2 2026 | 14% | +18 points |
| Q1 2026 | 10% | +9.6 points |
| Q4 2025 | 10% | +1 points |
| Q3 2025 | 14% | +12 points |
| Q2 2025 | -4.2% | -9 points |
| Q1 2025 | 0.7% | -1.2 points |
| Q4 2024 | 8.9% | +6.1 points |
COHR's operating margin was 15% last quarter, up 1.4 points from the same quarter a year ago, near the top of its range since 2019.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC has the edge over COHR on cash generation, producing positive trailing cash flow while its opponent burns cash.
COHR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$868.2M | -$810.2M |
| Q2 2026 | -$486.2M | -$485.2M |
| Q1 2026 | -$383.5M | -850% |
| Q4 2025 | -$95.7M | -217% |
| Q3 2025 | -$58M | -195% |
| Q2 2025 | -$1.1M | -102% |
| Q1 2025 | $51.1M | +111% |
| Q4 2024 | $81.7M | +$106M |
COHR's free cash flow has turned negative after years in the green: −$1.8B over the past year.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over COHR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
COHR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.4% | +6.6M shares |
| 1 year | +5.9% | +11.3M shares |
| 3 years | +34% | +51.7M shares |
| 5 years | +74% | +86.2M shares |
| Available history | +122% | +111M shares |
COHR has 202M diluted shares, up 5.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q2 2020 | — |
| Q1 2020 | $1,000 |
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
COHR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.5x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 3.5x | Elevated |
| Q3 2025 | 4.1x | High |
| Q2 2025 | 8.1x | High |
| Q1 2025 | 5.1x | High |
| Q4 2024 | 4.6x | High |
COHR has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
COHR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.6 | Neutral |
| Stochastic | 16.5 | Oversold |
COHR's weekly RSI is 44 (neutral) and its Stochastic is 16 (oversold).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC has the edge over COHR on valuation relative to its sector.
COHR PE vs Technology Sector
| Metric | COHR | Sector median | Relative |
|---|---|---|---|
| PE | 48x | 28x | 72% above |
| PE % | 58 | 35 | 23 pts above |
COHR is trading at 48x earnings, a 72% premium to the Technology sector's median of 28x.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
COHR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $252.9 | 8.2% below |
| 20 week MA | $284.1 | 18% below |
| 50 week MA | $277.7 | 16% below |
| 100 week MA | $185.9 | 25% above |
| 200 week MA | $120.6 | 92% above |
COHR has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
COHR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.5 | $77.8 | +132% |
| 2021 | $77.8 | $68.0 | -13% |
| 2022 | $68.0 | $33.1 | -51% |
| 2023 | $33.1 | $43.5 | +32% |
| 2024 | $43.5 | $97.0 | +123% |
| 2025 | $97.0 | $191.7 | +98% |
| 2026 YTD | $191.7 | $232.1 | +21% |
COHR has the edge over BAC on returns for 2026, with the stronger performance.